Business
PetLife Pharmaceuticals Announces pre-INAD (Investigational New Animal Drug) Cell Lines Study of Vitalzul™ has Begun
PetLife Pharmaceuticals Announces pre-INAD (Investigational New Animal Drug) Cell Lines Study of Vitalzul™ has Begun.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, Sept. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has commenced its pre-INAD (Investigational New Animal Drug) studies of VitalzulTM with the inception of a cell lines study to identify the appropriate targets for safety and efficacy testing. In conjunction with InnoVision Therapeutics, the study will verify cancer cell types that have already been determined to be responsive to VitazulTM and determine the most appropriate target indication for clinical trials once initial safety and dosing studies are completed.\n Cell lines studies are well accepted as one of the initial steps in drug development and testing 1,2. Standard cancer cell lines are prepared and exposed to VitalzulTM. The amount of cell death can be measured by laboratory assay methods. The cell types identified as most susceptible to VitalzulTM will be ranked in order of appropriateness for further studies based not only on the cell lines study, but also their prevalence and known response to conventional therapy. With this information, along with other studies to be announced shortly, the company anticipates scheduling a formal meeting with the FDA/CVM followed by application filing to the agency for approval of its clinical trial protocols. Dr. Ramana, PetLife Pharmaceutical’s Chief Medical Officer, noted “These studies will put PetLife Pharmaceuticals on a direct path towards providing strong evidence-based research to the FDA, demonstrating the efficacy of VitazulTM in the treatment of cancer in our companion animals. The experience of InnoVision Therapeutics with the human formulation “Escozine” provides an added level of confidence to our efforts.” CEO of PetLife Pharmaceuticals, Dr. Salvagno, commented “We are committed to moving this program forward in an expedited manner. Our recent capital raise is providing the funds to ensure that this process continues forward without interruption and with the full support of the entire PetLife team.” Petlife’s 506 Private Placement Memorandum is available only to accredited investors. References: 1)Daniela Ferreira, Filomena Adega and Raquel Chaves (2013). The Importance of Cancer Cell Lines as ...